Marinus Pharmaceuticals, Inc.
170 N Radnor Chester Road
Radnor
PA
19087
United States
Tel: 484-801-4674
Website: http://www.marinuspharma.com/
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to improving the lives of patients; women suffering from postpartum depression; children suffering from drug-resistant epilepsies such as CDKL5 deficiency disorder (a serious, rare genetic epilepsy), and rare behavior disorders, such as FXS (Fragile X Syndrome).
We are developing Ganaxolone in three different dose forms (IV, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is preparing to initiate a pivotal study in children with rare, CDKL5 deficiency disorder and currently conducting studies in postpartum depression and refractory status epilepticus.
Our team is determined to bring these drugs to the patients who need them; and improve their quality of life and the quality of life for their loved ones. We are seeking team members who want to be part of a dynamic and cohesive team ready use his/her talents to their full potential.
Stock Symbol: MRNS
Stock Exchange: Nasdaq
123 articles with Marinus Pharmaceuticals, Inc.
-
Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index
12/21/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to market open today.
-
Marinus Pharmaceuticals Announces Pricing of $70 Million Public Offering of Common Stock
12/8/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 5 million shares of its common stock for gross proceeds of $70 million,
-
Marinus Pharmaceuticals Provides Additional Ganaxolone Data During Scientific Exhibit at AES2020 Virtual Annual Meeting and Provides Corporate Update
12/7/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a virtual Scientific Exhibit at the American Epilepsy Society (AES) Annual Meeting (AES2020) from 8:00 AM to 11:00 AM Eastern Time today.
-
Marinus Pharmaceuticals Announces Underwritten Public Offering of Common Stock
12/7/2020
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by Marinus. Marinus has granted the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares offer
-
Marinus Launches Expanded Access Program for Ganaxolone Treatment in CDKL5 Deficiency Disorder
12/7/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the launch of an expanded access program that will allow the company to offer ganaxolone to patients with CDKL5 Deficiency Disorder who were unable to participate in the company’s Marigold Study Phase 3 clinical trial.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 04, 2020
12/4/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to two new employees.
-
Marinus Pharmaceuticals to Host Virtual Investor Event at AES On December 7, 2020
12/2/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in status epilepticus, CDKL5 deficiency disorder, and Tuberous sclerosis complex, on Monday, December 7 from 12:00 PM – 2:00 PM Eastern time.
-
Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting
11/23/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that four abstracts highlighting clinical trial and research data in the use of ganaxolone in treating CDKL5 deficiency disorder (CDD) and refractory status epilepticus (SE) have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting (AES2020)
-
Marinus Pharmaceuticals Announces Grants Under Nasdaq Listing Rule 5635(c)(4)
11/10/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (the “Company” or “Marinus”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of inducement awards to two (2) new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 134,000 shares of its
-
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
11/9/2020
Reported positive topline data from pivotal Phase 3 Marigold Study of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD) Awarded five-year cost-sharing contract with Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for refractory status epilepticus (RSE)
-
Marinus Pharmaceuticals Appoints Christy Shafer as Chief Commercial Officer
11/9/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that Christy Shafer has been appointed Chief Commercial Officer, reporting to Scott Braunstein, M.D., Chief Executive Officer of Marinus. “As we continue to build our senior team with formidable leaders, we believe Christy is the right person to
-
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020
10/20/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it will release financial results for the third quarter ended September 30, 2020 after the market closes on November 9, 2020.
-
Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences
10/19/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will participate in a Truist Virtual Fireside Chat, the Guggenheim Virtual Conference: 2nd Annual Neuro/Immunology Day and the Jefferies Global Healthcare Conference over the next few weeks. Additional details can be foun
-
Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update
10/19/2020
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Monday, October 26, 2020 at 4:30 p.m. EDT / 8:30 p.m. GMT to provide investors with an update on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, which was approved by the U.S. Food and Drug Administration on July
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 14, 2020
10/14/2020
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to 11 new employees.
-
Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)
9/24/2020
Sept. 24, 2020 20:01 UTC Marinus has satisfied the FDA’s protocol-specific questions for the Phase 3 trial in refractory status epilepticus (RSE) Company intends to begin enrollment for registrational Phase 3 clinical trial in RSE; over 55 out of projected 80 sites have been selected for trial participation Noted clinical expert in status epilepticus, Henri Vaitkevicius, M.D., has been appointed Vice President, Clinical Development
-
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. -
Shares of Marinus Pharmaceuticals soared more than 60% in after-hours trading Monday following the company’s announcement that its experimental epilepsy treatment ganaxolone hit the mark in a Phase III study.
-
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy
9/14/2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced positive top-line results from its registrational Phase 3 clinical trial (Marigold Study) evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures.
-
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences - Sep 08, 2020
9/8/2020
Marinus Pharmaceuticals, Inc. announced that management will present at the Morgan Stanley Virtual Global Healthcare Conference, H.C Wainwright Virtual Global Investment Conference and Cantor Virtual Global Healthcare Conference during the week of September 14.